Nrgene AI Stock Analysis
Want to see IL:NRGN full AI Analyst Report?
Nrgene (NRGN) AI Stock Analysis
Nrgene
(TASE:NRGN)
IL:NRGN is weighed down by severely bearish technical momentum and a lack of bottom-line profitability that pressures its valuation. However, the underlying business is showing signs of a fundamental turnaround, supported by triple-digit revenue growth, a highly de-risked balance sheet, and a recent inflection into positive free cash flow.
Nrgene (NRGN) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 8.13M
- Dividend Yield
- ―
- Average Volume (3M)
- 11.38K
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- 0.59
- Revenue Growth
- 115.63%
- EPS Growth
- 60.19%
- Country
- Israel
- Employees
- 23
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Software - Application
Nrgene Business Overview & Revenue Model
Company Description
NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides spec...
How the Company Makes Money
NRGene primarily generates revenue by commercializing access to its genomics analysis software/platform and related services for organizations conducting genetic research and breeding programs. Key revenue streams typically include (a) software licen...
Nrgene Financial Statement Overview
Summary
A pivotal turnaround year highlighted by 251% revenue growth, a transition to positive free cash flow, and a virtually debt-free balance sheet, though constrained by lingering net losses.
Income Statement
48NeutralBalance Sheet
68PositiveCash Flow
75Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.25M | 3.17M | 1.29M | 2.00M | 3.16M | 4.46M |
| Gross Profit | 1.92M | 1.92M | 267.00K | 901.00K | 1.71M | 2.46M |
| EBITDA | -1.98M | -965.00K | -2.69M | -4.53M | -5.59M | -8.10M |
| Net Income | -2.58M | -1.50M | -3.36M | -5.24M | -6.21M | -8.34M |
Balance Sheet | ||||||
| Total Assets | 7.12M | 9.54M | 6.00M | 10.79M | 17.30M | 26.36M |
| Cash, Cash Equivalents and Short-Term Investments | 3.18M | 5.30M | 1.37M | 6.45M | 12.28M | 22.87M |
| Total Debt | 145.02K | 181.00K | 288.00K | 797.00K | 1.61M | 3.34M |
| Total Liabilities | 4.66M | 5.13M | 2.00M | 3.57M | 5.04M | 8.68M |
| Stockholders Equity | 2.51M | 4.31M | 3.96M | 7.21M | 12.26M | 17.68M |
Cash Flow | ||||||
| Free Cash Flow | -511.43K | 72.00K | -5.19M | -5.58M | -7.83M | -6.67M |
| Operating Cash Flow | 268.11K | 855.00K | -3.56M | -3.91M | -6.12M | -5.57M |
| Investing Cash Flow | 364.72K | 455.00K | -1.30M | -1.27M | 12.47M | -14.83M |
| Financing Cash Flow | 42.23K | 1.53M | -317.00K | -410.00K | -2.46M | 27.59M |
Nrgene Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Negative. The current price of 61.30 is below the 20-day moving average (MA) of 65.91, below the 50-day MA of 80.59, and below the 200-day MA of 190.27, indicating a bearish trend. The MACD of -5.97 indicates Negative momentum. The RSI at 18.42 is Positive, neither overbought nor oversold. The STOCH value of 65.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NRGN.
Nrgene Peers Comparison
Overall Rating
IL:MTRX68Neutral
IL:NRGN52Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:NRGN | NRGENE TECHNOLOGIES LTD | 61.30 | -221.10 | -78.29% | |
| IL:MTRX | Matrix IT Ltd. | 10970.00 | -1747.82 | -13.74% | |
| IL:TECT | TECTONA LTD | 92.60 | -195.80 | -67.89% | |
| IL:MPRS | Mediprss Pu | 48.50 | -12.50 | -20.49% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 29, 2026
